Siemens Healthineers Ends General Ultrasound Sales to Focus on Procedural Imaging

Siemens Healthineers has stopped selling general imaging ultrasound systems and will focus its ultrasound business on procedural imaging and image-guided therapy, the company announced on October 12.

As of that date, the company said, it no longer sells general imaging systems including the Acuson Sequoia, Redwood, Juniper and Maple. It will continue to sell procedural ultrasound systems, namely the Acuson Origin, the P500 intracardiac echocardiography (ICE) system and Freestyle, together with dedicated software and catheters, mainly to electrophysiologists and interventional cardiologists.

A narrower ultrasound strategy

Siemens Healthineers said it will concentrate on cardiovascular interventions, software, artificial intelligence and partnerships that support physicians guiding minimally invasive procedures. The plan brings together the Acuson Origin cardiovascular imaging platform, the company's intracardiac echocardiography work, software and AI capabilities, and partnerships with cardiovascular device companies, according to the release.

Intracardiac echocardiography is a technique in which an ultrasound-tipped catheter is passed into the heart, MedTech Dive explained in its coverage. The publication noted that the Acuson Origin received Food and Drug Administration clearance in 2024 and includes AI features to help with measurements and view recognition.

"Medicine is evolving, and imaging is increasingly becoming part of therapy, not just diagnosis," said Sourabh Pagaria, head of ultrasound at Siemens Healthineers. "By concentrating our ultrasound portfolio on procedural imaging, we can apply our strengths in advanced cardiovascular imaging, ICE, software, AI, and partnerships with cardiovascular device companies to address important clinical needs and create long-term value for physicians, patients, and Siemens Healthineers."

The company described general imaging ultrasound as "a well-served market with solutions available from multiple established providers." It said it views procedural imaging as a significant opportunity for long-term growth.

Existing customers

Siemens Healthineers said it will continue to provide service and support for all existing customers in its installed base, "honoring all contractual and regulatory obligations." That support includes maintenance, software updates and transducer availability, according to the release. The company did not say how long full lifecycle support for the discontinued systems would last.

The announcement, datelined Issaquah, Washington, did not give figures for the size of the general imaging ultrasound business or say whether the change would affect staffing.

Part of a broader focus

MedTech Dive reported that Siemens Healthineers debuted a strategy last year to use artificial intelligence and partnerships to tackle prevalent diseases, and that the ultrasound change contributes to that effort. In its release, the company said it is focusing on some of the world's most pressing health challenges, including cancer, stroke, cardiovascular and neurodegenerative diseases.

Siemens Healthineers reported revenue of around €23.4 billion and approximately 74,000 employees in fiscal 2025, which ended on September 30, 2025, according to the company's boilerplate. The group's parent, Siemens Healthineers AG, is listed in Frankfurt.